The consensus price target hints at a 36.9% upside potential for Lumexa (LMRI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Lumexa Imaging Holdings, Inc. (LMRI) Q2 2026 Earnings Call Transcript
Lumexa Imaging NASDAQ: LMRI reported second-quarter revenue growth, higher advanced-imaging volumes and a return to profitability, while narrowing its full-year adjusted EBITDA outlook and reiterating revenue and adjusted earnings-per-share guidance.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 61,606 | $694,915.68 | $713,397.48 | $18,481.8 | 2.66% |
Point72 Asset Management LP Point72 Asset Management LP | 280,963 | $3.87M | $3.38M | -$492,357.98 | -12.72% |
Joseph Castro Nuveen LLC | 32,520 | $287,861.62 | $381,784.8 | $93,923.18 | 32.63% |
| TC Thomas Cagna Sandia Investment Management LP | 10,000 | $185,000 | $104,100 | -$80,900 | -43.73% |
Taro Kuriyama Axq Capita LLP | 11,356 | $128,096 | $118,215.96 | -$9,880.04 | -7.71% |
| Health Care Equipment & Supplies Industry | Healthcare Sector | Caitlin Zulla CEO | NASDAQ (NGS) Exchange | 550249106 CUSIP |
| US Country | 5,000 Employees | - Last Dividend | - Last Split | - IPO Date |